Latest Pharma and Biotech News
Pharmaceutical
4 April 2025 A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.
Today's issue
Refine Search
Pharmaceutical
A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced. 4 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Swedish biotech OncoZenge has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies. 4 April 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive condition that runs in families caused by a protein called transthyretin (TTR). 4 April 2025
Pharmaceutical
US biotech Aldeyra Therapeutics has received a Complete Response Letter from the US Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of its dry eye disease candidate reproxalap. 4 April 2025
Pharmaceutical
US pharma major Eli Lilly’s brand value has surged by 108% since entering the weight loss market in 2023, according to a new report from Brand Finance. 3 April 2025
Pharmaceutical
Colorado, USA-based Edgewise Therapeutics, a muscle disease-focused biopharma company, closed 23% lower after Wednesday’s trading. 3 April 2025
Pharmaceutical
With two new lawsuits, Eli Lilly has escalated its legal campaign against the makers of unauthorized versions of its diabetes and weight-loss drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide), challenging inroads made by drug compounders in what has become a highly lucrative market. 3 April 2025
Pharmaceutical
Pharmaceuticals will be exempt from the tariffs on imports to the USA that were announced by US President Donald Trump Wednesday, according to a White House fact sheet. 3 April 2025
Pharmaceutical
Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. 3 April 2025
Pharmaceutical
CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol in major depressive disorder (MDD) with and without severe excessive daytime sleepiness (EDS). 3 April 2025
Pharmaceutical
The American Gastroenterological Association (AGA) has recently released a major update to its clinical guideline for the pharmacological management of moderate-to-severe ulcerative colitis (UC). 2 April 2025
Pharmaceutical
Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt Pharmaceuticals and Endo, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 2 April 2025
Pharmaceutical
Boehringer Ingelheim, now Germany's largest pharma company, today reported a currency-adjusted 6.1% gain in full-year 2024 revenues, buoyed by its diabetes and lung drugs. 2 April 2025
Pharmaceutical
Freed from their former obligations to remain loyal to agency and state, a number of high-profile figures from the US Food and Drug Administration (FDA) have sounded the alarm about its direction of travel under Robert Francis Kennedy Jr (RFK Jr), the new Secretary of Health and Human Services. 2 April 2025
Pharmaceutical
French drugmaker Sanofi has appointed Chris Corsico as its new global head of development, according to an internal company communication obtained by The Pharma Letter. 2 April 2025
Pharmaceutical
Danish biotech Gubra saw its share gains more than 8% to 448.00 kroner, after it announced positive results from the single ascending dose (SAD) Phase I clinical trial with the long-acting amylin analogue GUBamy (GUB014295). 2 April 2025
Pharmaceutical
UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, untreated Parkinson’s disease, that failed to meet the primary endpoint of the study. 2 April 2025
Pharmaceutical
Japanese drugmaker Sumitomo Pharma said yesterday that it is divesting its Asian business to major Japanese trading house Marubeni for roughly 72 billion yen ($480 million) in a deal that forms part of its post-Latuda (lurasidone) turnaround efforts. 2 April 2025
All news
Pharmaceutical
At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. 14 March 2025
Pharmaceutical
Japan’s Shionogi yesterday delivered a late-breaking scientific oral presentation at the Conference of Retroviruses and Opportunistic Infections (CROI) 2025 on its ensitrelvir. 14 March 2025
Pharmaceutical
Swiss drugmaker Idorsia has announced the publication of a Phase IV study in the Journal of Sleep Research. 14 March 2025
Pharmaceutical
Hours before his confirmation hearing, the Trump Administration pulled the nomination of Dr Dave Weldon to be the director of the Centers for Disease Control and Prevention (CDC). 14 March 2025
Pharmaceutical
Ireland-based Mallinckrodt Pharmaceuticals and Endo Inc have agreed to combine in a stock and cash deal worth $6.7 billion, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 13 March 2025
Pharmaceutical
UK-based Sareum Holdings (AIM: SAR), a biotech developing kinase inhibitors for autoimmune disease and cancer, has acquired the licence for SRA737 following the program’s return from an undisclosed USA-based biopharma. 13 March 2025
Pharmaceutical
Privately-held Ashvattha Therapeutics, a Californian firm advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, has announced positive Phase II data for migaldendranib, a novel subcutaneously (subQ) administered nanomedicine treatment for retinal diseases. 13 March 2025
Pharmaceutical
The European Commission (EC) has approved Danish CNS specialist Lundbeck and Otsuka Pharmaceutical Europe’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. 13 March 2025
Pharmaceutical
Germany’s Heidelberg Pharma has modified its royalty financing agreement with HealthCare Royalty (HCRx), securing an additional $20 million upfront payment. 13 March 2025
Pharmaceutical
Insilico Medicine has raised $110 million in a series E funding round to drive the development of its artificial intelligence-powered drug candidates, including its leading drug for idiopathic pulmonary fibrosis (IPF). 13 March 2025
Pharmaceutical
US pharma giant Merck & Co has presented positive results from two pivotal Phase III trials of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF (50mg/200mg/25mg)] in trial MK-8591A-052 ) or antiretroviral therapy [baseline antiretroviral therapy (bART)] in trial MK-8591A-051. 13 March 2025
Pharmaceutical
California-based Vivace Therapeutics has announced the closing of a $35 million Series D financing. 13 March 2025
Pharmaceutical
Specialist HIV company ViiV Healthcare, which is majority owned by UK pharma major GSK, today announced positive findings from the company’s EMBRACE Phase IIb study. 12 March 2025
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has entered into a license agreement with USA-based Ionis Pharmaceuticals for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Ionis’ shares edged up 2.4% to $33.82 on the news. 12 March 2025
Pharmaceutical
Sweden-based women’s health company Gedea Biotech has completed a clinical trial, the NEFERTITI-2 study, for the treatment of bacterial vaginosis. 12 March 2025
Pharmaceutical
Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, following the implementation of Veeva Systems' Development Cloud. 12 March 2025
Pharmaceutical
ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 and VH499. 12 March 2025
Pharmaceutical
Shares of Danish biotech Zealand Pharma were up 30% at 635.50 kroner by early afternoon, on news of a potentially lucrative licensing deal with Swiss pharm giant Roche. 12 March 2025
Pharmaceutical
US biopharma Viking Therapeutics developing therapies for metabolic and endocrine disorders, closed Tuesday’s trading 5% lower. 12 March 2025
Pharmaceutical
California commercial-stage biopharma firm Geron Corporation has announced that Dr John “Chip” Scarlett, president, chief executive (CEO) and chairman, will depart the company on March 31, 2025. 12 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze